A Study of MSB0254 Injection in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the
safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or
metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.